Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

NEUROFIBROMATOSIS, INC., NORTHEAST

Filed by VAN SCOYOC ASSOCIATES.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 18, 2025
Income
Not reported
Expenses
Not reported
Filing UUID
8bf053bd-884c-4b3a-9bcf-26830a2331b9
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

DEF · Defense

Medical research issues and Neurofibromatosis provisions, as follows: Public Law 119-4, Full-Year Continuing Appropriations and Extensions Act, FY2025 H.R.4016, Department of Defense Appropriations Act, FY2026

Literal federal measure citations: H.R.4016

BUD · Budget/Appropriations

Medical research issues and Neurofibromatosis provisions, as follows: Public Law 119-4, Full-Year Continuing Appropriations and Extensions Act, FY2025 H.R.4016, Department of Defense Appropriations Act, FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2026

Literal federal measure citations: H.R.4016

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.